Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 28;17(10):3747–3756. doi: 10.1080/21645515.2021.1932217

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 GlaxoSmithKline Biologicals S.A. Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — Study design

D0, day of the first vaccine dose; D42, day of the second vaccine dose (Day 42, administered six weeks after the first vaccine dose); D84, follow-up timepoint at six weeks after the second vaccine dose – Day 84; Y, year; Y1-Y10, regular blood sampling and follow-up timepoints after the second vaccine dose (after one, two, four, six, eight, and ten years); Active Control, participants receiving two doses of trivalent measles-mumps-rubella vaccine (MMR); MMRV, participants receiving two doses of the tetravalent MMR-varicella vaccine; MMR+V, participants receiving one dose of MMR and one dose of monovalent varicella vaccine; 1:3:3, randomization format of participants in the treatment groups (Active control: MMRV: MMR+V); VZV, varicella-zoster virus; Ab, antibodies.